Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.53 |
| ▸ | HTR7 | P34969 | 4/20 | 0.46 |
| ▸ | HTR1B | P28222 | 1/20 | 0.44 |
| ▸ | ESR1 | P03372 | 2/20 | 0.43 |
| ▸ | DRD2 | P14416 | 1/20 | 0.41 |
| ▸ | DRD1 | P21728 | 1/20 | 0.41 |
| ▸ | DRD4 | P21917 | 1/20 | 0.41 |
| ▸ | DRD5 | P21918 | 1/20 | 0.41 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.39 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.39 |
| ▸ | LTA4H | P09960 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16240198 | 0.83 | HTR7 (0.60) | KDM4EHTR7HTR1BDRD2DRD1 | |
| SCHEMBL27991741 | 0.83 | ESR1 (0.44) | KDM4EHTR7HTR1BESR1DRD2 | |
| SCHEMBL3419949 | 0.83 | HTR7 (0.44) | KDM4EHTR7HTR1BDRD2DRD1 | |
| SCHEMBL4577229 | 0.83 | HTR7 (0.53) | KDM4EHTR7HTR1BDRD2DRD1 | |
| SCHEMBL2479633 | 0.83 | HTR7 (0.53) | KDM4EHTR7HTR1BDRD2DRD1 | |
| SCHEMBL3463971 | 0.81 | HTR7 (0.42) | KDM4EHTR7HTR1BESR1DRD2 | |
| SCHEMBL188652 | 0.81 | CYP1A2 (0.47) | KDM4EHTR1BHRH3ALDH1A1SMN1; SMN2 | |
| SCHEMBL17046320 | 0.79 | MAPT (0.38) | KDM4EESR1ALDH1A1SMN1; SMN2CYP1A2 | |
| SCHEMBL28551358 | 0.79 | ROCK2 (0.45) | KDM4EHTR7HTR1BDRD2DRD1 | |
| SCHEMBL19925872 | 0.79 | ESR1 (0.44) | KDM4EHTR7HTR1BESR1DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240043384-A1 | INHIBITORS OF PU.1 FOR THE TREATMENT OF DISEASE | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2024-02-08 | — | — | US | claimed |
| US-20240043384-A1 | INHIBITORS OF PU.1 FOR THE TREATMENT OF DISEASE | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2024-02-08 | — | — | US | disclosed |
| US-8288396-B2 | Pyrimidopyrimidoindazole derivative | MSDKK (JP) | 2012-10-16 | — | — | US | disclosed |
| US-20120134955-A1 | PYRIMIDOPYRIMIDOINDAZOLE DERIVATIVE | MSD K.K. (JP) | 2012-05-31 | — | — | US | disclosed |
| EP-2401281-A1 | PYRIMIDOPYRIMIDOINDAZOLE DERIVATIVE | MSD K.K. (JP) | 2012-01-04 | — | — | EP | disclosed |
| WO-2010098367-A1 | PYRIMIDOPYRIMIDOINDAZOLE DERIVATIVE | BANYU PHARMACEUTICAL CO.,LTD. (JP) | 2010-09-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240043384-A1 | INHIBITORS OF PU.1 FOR THE TREATMENT OF DISEASE | CREBBP, JUN, SP1 | KDM4E 1875/4885HTR7 3919/4885HTR1B 3743/4885 |
| US-20120134955-A1 | PYRIMIDOPYRIMIDOINDAZOLE DERIVATIVE | WEE1, WEE2, DCK | KDM4E 1155/4885HTR7 4068/4885HTR1B 3132/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.